ARTICLE | Company News

Knight Therapeutics, Medicure cardiovascular news

April 21, 2014 7:00 AM UTC

Medicure hired Knight as an advisor to advance the company's U.S. specialty pharmaceutical business and "corporate development initiatives." Medicure has rights from Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) to Aggrastat tirofiban in the U.S., where it markets the non-peptide integrin alpha(2b)beta(3) ( GPIIb/IIIa; CD41/CD61) antagonist in combination with heparin to treat acute coronary syndrome (ACS), including patients who are to be managed medically and those undergoing percutaneous transluminal angioplasty (PTCA) or atherectomy. At Feb. 28, Medicure had C$44,774 ($40,225) in cash and a nine-month net loss of C$902,404 ($810,720). Knight declined to provide further details, and Medicure could not be reached. ...